These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 15078984)
1. Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci. Camphausen K; Brady KJ; Burgan WE; Cerra MA; Russell JS; Bull EE; Tofilon PJ Mol Cancer Ther; 2004 Apr; 3(4):409-16. PubMed ID: 15078984 [TBL] [Abstract][Full Text] [Related]
2. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Raju U; Nakata E; Mason KA; Ang KK; Milas L Cancer Res; 2003 Jun; 63(12):3263-7. PubMed ID: 12810657 [TBL] [Abstract][Full Text] [Related]
3. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases. Raju U; Ariga H; Koto M; Lu X; Pickett J; Valdecanas D; Mason KA; Milas L Radiother Oncol; 2006 Aug; 80(2):185-91. PubMed ID: 16905211 [TBL] [Abstract][Full Text] [Related]
4. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells. Jung C; Motwani M; Kortmansky J; Sirotnak FM; She Y; Gonen M; Haimovitz-Friedman A; Schwartz GK Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6052-61. PubMed ID: 14676132 [TBL] [Abstract][Full Text] [Related]
5. Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Wu K; Wang C; D'Amico M; Lee RJ; Albanese C; Pestell RG; Mani S Mol Cancer Ther; 2002 Jul; 1(9):695-706. PubMed ID: 12479366 [TBL] [Abstract][Full Text] [Related]
6. Flavopiridol potentiates the cytotoxic effects of radiation in radioresistant tumor cells in which p53 is mutated or Bcl-2 is overexpressed. Hara T; Omura-Minamisawa M; Kang Y; Cheng C; Inoue T Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1485-95. PubMed ID: 18640498 [TBL] [Abstract][Full Text] [Related]
7. Flavopiridol as a radio-sensitizer for esophageal cancer cell lines. Sato S; Kajiyama Y; Sugano M; Iwanuma Y; Tsurumaru M Dis Esophagus; 2004; 17(4):338-44. PubMed ID: 15569374 [TBL] [Abstract][Full Text] [Related]
8. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Jung CP; Motwani MV; Schwartz GK Clin Cancer Res; 2001 Aug; 7(8):2527-36. PubMed ID: 11489836 [TBL] [Abstract][Full Text] [Related]
9. Rhabdoid tumor growth is inhibited by flavopiridol. Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228 [TBL] [Abstract][Full Text] [Related]
10. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881 [TBL] [Abstract][Full Text] [Related]
11. Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol. Smith V; Raynaud F; Workman P; Kelland LR Mol Pharmacol; 2001 Nov; 60(5):885-93. PubMed ID: 11641415 [TBL] [Abstract][Full Text] [Related]
12. Growth inhibition and induction of apoptosis by flavopiridol in rat lung adenocarcinoma, osteosarcoma and malignant fibrous histiocytoma cell lines. Honoki K; Yoshitani K; Tsujiuchi T; Mori T; Tsutsumi M; Morishita T; Takakura Y; Mii Y Oncol Rep; 2004 May; 11(5):1025-30. PubMed ID: 15069542 [TBL] [Abstract][Full Text] [Related]
13. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Alonso M; Tamasdan C; Miller DC; Newcomb EW Mol Cancer Ther; 2003 Feb; 2(2):139-50. PubMed ID: 12589031 [TBL] [Abstract][Full Text] [Related]
14. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia. Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730 [TBL] [Abstract][Full Text] [Related]
15. Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity. Jiang J; Matranga CB; Cai D; Latham VM; Zhang X; Lowell AM; Martelli F; Shapiro GI Cancer Res; 2003 Nov; 63(21):7410-22. PubMed ID: 14612540 [TBL] [Abstract][Full Text] [Related]
16. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Motwani M; Rizzo C; Sirotnak F; She Y; Schwartz GK Mol Cancer Ther; 2003 Jun; 2(6):549-55. PubMed ID: 12813134 [TBL] [Abstract][Full Text] [Related]
18. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Motwani M; Delohery TM; Schwartz GK Clin Cancer Res; 1999 Jul; 5(7):1876-83. PubMed ID: 10430095 [TBL] [Abstract][Full Text] [Related]
19. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells. Motwani M; Li X; Schwartz GK Clin Cancer Res; 2000 Mar; 6(3):924-32. PubMed ID: 10741717 [TBL] [Abstract][Full Text] [Related]
20. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Camphausen K; Burgan W; Cerra M; Oswald KA; Trepel JB; Lee MJ; Tofilon PJ Cancer Res; 2004 Jan; 64(1):316-21. PubMed ID: 14729640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]